No benefit to selecting dose of blood thinner based on patients' genetic makeup

According to a new study conducted at the Perelman School of Medicine at the University of Pennsylvania has found that a gene-based method for selecting patients' doses of the popular heart medication warfarin is not affective as the other recommended procedures. The study published in the New England Journal of Medicine. It has been proved that the Warfarin is a blood thinner that is used to prevent clots and is also generally considered to be a very effective medication, but it should be dosed properly.The lead study author Stephen Kimmel, MD, MSCE, professor of Medicine and Epidemiology at Penn Medicine explains, “There has been much interest in the medical community about the utility of pharmacogenetics – using information about a person's genetic makeup to choose the drugs and drug doses that are most likely to work well for that particular person – to help better personalize treatments for patients and improve drug safety and efficacy.”